Hyaluronic acid (HA) viscosupplementation has one of the largest injection evidence bases in OA — 76 placebo-controlled trials — and most guideline bodies now recommend against it. That combination is unusual and worth understanding.
ACR/AF 2019: Conditionally recommends against HA for knee OA and first CMC joint; strongly recommends against HA for hip OA. The evidence was judged insufficient to overcome the placebo response to the injection procedure. AAOS 2022: Moderate "viscosupplementation should not be considered standard treatment for routine use" (knee); Strong "should not be considered" (hip). NICE NG226: "Do not offer" viscosupplementation for OA. OARSI 2019: Conditional for — recommends HA for knee OA. OARSI is an outlier; its conditional-for recommendation predates the 2022 BMJ meta-analysis.
Ye J et al. (BMJ Open, 2022) — primary analysis: 76 placebo-controlled trials included. Effect versus sham: approximately 2 mm on a 100 mm VAS — below the MCID (typically 15–20 mm). Serious adverse events: 1.49 times higher versus sham across included trials. This is the meta-analysis underpinning the guideline shifts. The Fazilat-Panah 2025 sham-controlled LDRT trial reported statistically significant primary endpoint benefit exceeding MCID in favor of LDRT.
169 total trials / 21,163 patients for HA. 76 placebo-controlled — the largest placebo-controlled evidence base of any injectable OA treatment. That volume makes the answer about HA very precise: the effect versus sham is approximately 2 mm on 100 mm VAS, below clinical significance. More evidence has produced a more certain answer — that the effect is small.
Medicare covers HA viscosupplementation for knee OA (typically once per year per knee). LDRT coverage is variable. In plans where HA is covered but LDRT is not, this is a practical factor in decision-making.
HA may be reasonable for patients who have responded to it before, or where LDRT is inaccessible. LDRT may be more appropriate for patients who have not responded to HA injection series, who prefer non-injection treatment, or who want a single treatment course.
Related: All comparisons | LDRT vs. PRP | Am I a candidate?
Medically reviewed by: Robert Warren Floyd, M.D., Ph.D. — Resident Physician, Radiation Oncology, The University of Texas MD Anderson Cancer Center. Last reviewed: August 2, 2026. Independent personal project — not affiliated with or endorsed by MD Anderson Cancer Center. Funding & independence disclosure.